Page URL: https://www.bionews.org.uk/page_89871

HFEA seeks views on embryo tests for 'lower penetrance' disorders

10 November 2005
By BioNews
Appeared in BioNews 334

The UK's Human Fertilisation and Embryology Authority (HFEA) has launched a public debate on testing embryos for 'lower penetrance', late onset genetic disorders. A discussion paper, entitled 'Choices and Boundaries', focuses both on genetic tests currently available, such as that for hereditary breast cancer, and possible future developments, such as tests for inherited forms of Alzheimer's disease. Responses to the paper, which is available via the HFEA's website, are invited until 16 January 2006. The HFEA is also holding a public meeting on this subject, on 12 December 2005.

PGD involves taking a single cell from a 2-4 day old embryo created using in IVF performing a genetic or chromosome test on that cell, and then returning one or two unaffected embryos to the womb. In the UK, the use of PGD is regulated by the HFEA, which licenses the procedure on a case-by-case basis. The use of PGD to avoid later onset genetic conditions sparked debate last year, following the HFEA's decision to grant a licence to a team at University College Hospital, London, to use PGD to help couples avoid passing on hereditary bowel cancer to their children.

The discussion paper focuses on disorders where the conditions are not 'fully penetrant' (where not all people with the faulty gene will get the disease), such as hereditary forms of breast cancer. It asks questions such as 'How likely does a disease have to be for embryo testing to be acceptable?' and 'What type of condition should never be tested for in embryos, taking into account the chance of disease, age of onset and treatment available?' It also seeks views on possible future uses of PGD, including inherited forms of Alzheimer's disease, hereditary prostate cancer and inherited brain cancers. In the US, PGD has already been carried out for a couple at risk of passing on a rare, early-onset form of Alzheimer's disease.

Suzi Leather, chair of the HFEA, said the authority wants to hear from patients, carers, affected families, doctors and staff in treatment centres, as well as parliamentarians, academics and the wider public. 'This way we can begin to balance the views and interests of all groups and move towards building a consensus', she added.

Josephine Quintavalle, of the pro-life pressure group Comment on Reproductive Ethics (CORE) said that extending the potential uses of PGD was 'moving towards eugenics'. She told the BBC News website that 'it's all about making endless decisions about who is better off dead'. But Ainsley Newson, a medical ethicist at Imperial College London, said that for couples at risk of passing on a genetic condition, PGD offers 'a real alternative to terminating a wanted pregnancy'. She acknowledged that questions about seriousness would always arise, but asked: 'if we wouldn't wish these diseases on anyone then why shouldn't we let couples avoid this happening to their own children?'

SOURCES & REFERENCES
Embryo disease check views sought
BBC News Online |  10 November 2005
Should we be allowed to test at conception for conditions such as Alzheimer's?
HFEA |  10 November 2005
Views on embryo screening sought
The Daily Mail |  10 November 2005
RELATED ARTICLES FROM THE BIONEWS ARCHIVE
10 August 2009 - by Ben Jones 
A Chinese firm has begun offering DNA testing of children for 11 genes which it claims can be used to predict the child’s future talents and thus allow parents to target their rearing of the child towards its supposed latent potential. The Shanghai Biochip Corporation, which provides the test...
4 April 2007 - by Dr Jess Buxton 
According to the Sunday Times newspaper, a UK clinic is requesting permission to test embryos in order to select those free from early onset Alzheimer's disease. Charl and Danielle de Beer are planning undergo IVF treatment in conjunction with preimplantation genetic diagnosis (PGD) at the Bridge...
11 May 2006 - by Dr Jess Buxton 
The UK's fertility treatment regulator has given the go-ahead for couples to test embryos to avoid passing on hereditary cancer. At its open meeting held on 10 May in Belfast, the Human Fertilisation and Embryology Authority (HFEA) accepted a recommendation from its ethics and law committee...
11 August 2005 - by BioNews 
The UK's Human Fertilisation and Embryology Authority (HFEA) is to issue a public consultation on the use of preimplantation genetic diagnosis (PGD) for late-onset and 'lower penetrance' genetic disorders. The use of this technology to avoid later onset genetic conditions sparked debate recently, following the authority's decision to grant a...
4 May 2005 - by Mohammed Taranissi 
Like so many areas of new reproductive and genetic technology, PGD for susceptibility and late onset disorders needs careful attention. It raises some unique questions, and the recent decision of the Human Fertilisation and Embryology Authority (HFEA) to license PGD for bowel cancer has attracted much criticism from those who...
7 March 2005 - by BioNews 
US researchers have identified a gene mutation linked to an increased risk of Alzheimer's disease. The team, based at the Massachusetts General Hospital, say that it is only the second gene ever to be linked to the late-onset form of the disorder. The results, published in the New England Journal...
1 November 2004 - by BioNews 
The UK's Human Fertilisation and Embryology Authority (HFEA) has issued a licence allowing doctors to test embryos for a gene mutation that confers a high risk of bowel cancer. Four couples at risk of passing on familial adenomatous polyposis coli (FAP) to their children are now set to undergo the...
29 October 2001 - by BioNews 
Researchers at DeCODE genetics, the Rekyavik-based company studying the genetic records of the Icelandic population, announced last week that it had discovered a gene linked to the main form of Parkinson's disease. The gene was found on a small section of chromosome one after a study of data from 51...
HAVE YOUR SAY
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions


Syndicate this story - click here to enquire about using this story.